Anti-Alpha-synuclein antibody [MJFR1],Abcam,AB138501

Anti-Alpha-synuclein antibody [MJFR1] (ab138501) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P, IP and WB. Anti-Alpha-synuclein antibody [MJFR1] (ab138501) was first used in a scientific publication in 2012 and has been cited over 156 times in peer reviewed journals. It's performance in Western Blot in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Alpha-synuclein antibody [MJFR1] (ab138501) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Alpha-synuclein antibody [MJFR1] (ab138501) has been confirmed by Western Blot testing in Alpha-synuclein knockout HEK-293T cells ( ab263769 ). Anti-Alpha-synuclein antibody [MJFR1] (ab138501) has 7 independent reviews from customers. Anti-Alpha-synuclein antibody [MJFR1] (ab138501) specifically detects Alpha-synuclein (UniProt ID: P37840; Molecular weight: 15kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone MJFR1 - ab156369 . Antibody clone MJFR1 is also available pre-conjugated to a variety of labels for your convenience - Biotin, HRP ( ab309388 , ab314243 ). Anti-Alpha-synuclein antibody [MJFR1] (ab138501) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research. Alpha-Synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. This antibody was developed with support from The Michael J. Fox Foundation, in collaboration with the laboratory of Dr. Michael Schlossmacher (University of Ottawa). Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Species reactivity Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.